Show simple item record

AuthorAlhmoud, Eman N.
AuthorBarazi, Raja
AuthorFahmi, Amr
AuthorAbdu, Abdullah
AuthorHigazy, Alya
AuthorElHajj, Maguy
Available date2025-03-13T07:43:57Z
Publication Date2020
Publication NameJournal of Pharmaceutical Health Services Research
ResourceScopus
Identifierhttp://dx.doi.org/10.1111/jphs.12371
ISSN17598885
URIhttp://hdl.handle.net/10576/63626
AbstractObjective: The aim of the study was to assess the quality of the recently published European clinical practice guidelines for the management of dyslipidaemias, utilizing the refined Appraisal of Guidelines for Research & Evaluation tool. Method: The 2019 European Society of Cardiology and European Atherosclerosis Society Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk was appraised and scored for methodological rigour and transparency by 5 independent appraisers using a validated tool. Key findings: The guideline scored highest in the domains that evaluated editorial independence (100%) and clarity of presentation (98.6%) and lowest in the domains that addressed stakeholder involvement (55.56%) and rigour of development (63%). Overall the quality of the guideline was high, and all reviewers recommended its use in practice. Conclusion: The guideline's overall quality was judged to be high, and all appraisers recommended its use in practice without modifications.
Languageen
PublisherBlackwell Publishing Ltd
Subjectcardiovascular risk
clinical practice guidelines
dyslipidaemias
EAS
ESC
management
TitleCritical Appraisal of the Clinical Practice Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk: European Society of Cardiology (ESC) and European Atherosclerosis Society (ESC/EAS) 2019 Guidelines
TypeArticle
Pagination423-427
Issue Number4
Volume Number11
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record